Rheumatology (Oxford, England) · 2025
Telitacicept add-on therapy in refractory idiopathic inflammatory myopathy: insights from a pilot study.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gao Huajie, Lin Jing, Yang Mengge, Gui Mengcui, Ji Suqiong, Bu Bitao, Li Yue
Аннотация
OBJECTIVES: This study aimed to evaluate the therapeutic efficacy of telitacicept based on the conventional treatment in adults with idiopathic inflammatory myopathy (IIM), focusing on its impact on clinical manifestations.
METHODS: IIM patients who had been treated with telitacicept for at least 3 months based on the conventional treatment from January 2023 to January 2024 were included in this study. The clinical response to telitacicept was determined based on the ACR/EULAR criteria for minimal, moderate and major improvement in the Total Improvement Score. Disease activity was monitored using core set measures, while myositis damage was assessed with established assessment tools. The Manual Muscle Test for eight muscle groups (MMT-8) was used to assess the muscle performance.
RESULTS: A total of 11 patients administered with telitacicept (160 mg per week) were included in this study. Post-treatment assessments revealed improvements in all patients according to ACR/EULAR criteria. Notably, there was a significant reduction in the prednisone dosage from baseline to last visit [27.05 (12.47) to 12.05 (7.32) mg; P < 0.005]. An enhancement was observed in the MMT-8 score [which improved from 109.18 (14.18) to 137.64 (15.28); P < 0.005], and there was a reduction in creatine kinase level [from 2670.27 (2675.00) to 561.09 (754.09) U/l; P < 0.05].
CONCLUSION: Telitacicept demonstrated effectiveness in treating refractory inflammatory myopathy, contributing to a significant reduction in steroid dosage among the patients. These findings highlight the potential of telitacicept as a valuable therapeutic option in the management of IIM.
METHODS: IIM patients who had been treated with telitacicept for at least 3 months based on the conventional treatment from January 2023 to January 2024 were included in this study. The clinical response to telitacicept was determined based on the ACR/EULAR criteria for minimal, moderate and major improvement in the Total Improvement Score. Disease activity was monitored using core set measures, while myositis damage was assessed with established assessment tools. The Manual Muscle Test for eight muscle groups (MMT-8) was used to assess the muscle performance.
RESULTS: A total of 11 patients administered with telitacicept (160 mg per week) were included in this study. Post-treatment assessments revealed improvements in all patients according to ACR/EULAR criteria. Notably, there was a significant reduction in the prednisone dosage from baseline to last visit [27.05 (12.47) to 12.05 (7.32) mg; P < 0.005]. An enhancement was observed in the MMT-8 score [which improved from 109.18 (14.18) to 137.64 (15.28); P < 0.005], and there was a reduction in creatine kinase level [from 2670.27 (2675.00) to 561.09 (754.09) U/l; P < 0.05].
CONCLUSION: Telitacicept demonstrated effectiveness in treating refractory inflammatory myopathy, contributing to a significant reduction in steroid dosage among the patients. These findings highlight the potential of telitacicept as a valuable therapeutic option in the management of IIM.